Biophytis S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BPTS research report →
Companywww.biophytis.com
Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.
- CEO
- Stanislas Veillet
- IPO
- 2021
- Employees
- 22
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $2.61M
- P/E
- -0.05
- P/S
- 0.00
- P/B
- -0.05
- EV/EBITDA
- -1.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 92.02%
- ROIC
- -3022.97%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-17,026,000 · 29.69%
- EPS
- $-12.55 · 77.61%
- Op Income
- $-14,333,000
- FCF YoY
- 31.55%
Performance & Tape
- 52W High
- $168.80
- 52W Low
- $8.05
- 50D MA
- $16.44
- 200D MA
- $35.77
- Beta
- 1.05
- Avg Volume
- 9.04K
Get TickerSpark's AI analysis on BPTS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BPTS Coverage
We haven't published any research on BPTS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BPTS Report →